News

01.02.2008 4th Biomarker Workshop at the NMI in Reutlingen another success

“The workshop has become well established and continues to present excellent speakers and new insights into proteomics,” said Prof. Dr. Hugo Hämmerle, the new director of the NMI Natural and Medical Sciences Institute, opening this year’s Biomarker Workshop on 30th January 2008. The experienced organisational team under the direction of Dr. Thomas Joos (NMI Reutlingen) and Dr. Jutta Bachmann (BioChipNet) once more presented an exceptional programme. Joos was pleased that all invited speakers accepted the invitation to come to Reutlingen – an indication of excellence and the great reputation of the workshop.

The distinguished speakers were headed off by Dr. Oliver Steinbach, head of “Bio-Molecular Engineering” at Philips, who portrayed the latest developments in the Philips research labs in Eindhoven. Steinbach highlighted the increasing importance of molecular imaging in all areas of medicine, from research to preclincial drug development and diagnostics. The development of new and more effective technical solutions goes hand in hand with the development of a growing and more specific repertoire of targeted contrast agents that can be directed to specific places in the body where there is evidence of disease using biomarkers, which are a key research topic at the NMI, a major proteomics centre, as Steinbuch put it.

Biomarkers are increasingly used in research and medicine
Dr. Thomas Caskey, a renowned researcher in molecular medicine (Houston, Texas, USA), presented on stem cell research. Caskey is the head of Molecular Medicine at the University of Texas and directs the Research Institute for Molecular Medicine of the Brown Foundation. Caskey and his team used molecular genetic methods to differentiate embryonic stem cells into lung tissue cells (alveolar type II cells). Using specific biomarkers, Caskey’s team was able to characterise the cells and identify the correct degree of differentiation.

In the third presentation, Dr. Hanno Langen (head of Proteomics at Hoffmann-La Roche in Basel, Switzerland) introduced innovative technologies in biomarker development that provide new prospects. Using the search for colon cancer markers as an example, Langen presented the time-consuming process of selecting suitable biomarker candidates. Dr. Mike Spain (Rules Based Medicine, Texas, USA) continued by portraying the use of biomarkers in simple ex-vivo methods in order to test drug candidates in whole blood cultures. Rules Based Medicine (RBM) is an international leader in the identification of biomarkers using multiplex technologies. In autumn 2007, RBM acquired EDI GmbH in Reutlingen.

Market opportunities for proteome-based technologies

Dr. Hans Berger (HB Consulting, Graz, Austria) presented a completely different perspective by elucidating the most important patents in the area of protein microarrays, their beginnings and the chances of new technologies. A specific class of substances, which has alone in the USA led to more than 400 patents and patent applications, are aptamers. These short single-strand nucleotides have a particular 3D structure and only bind to certain molecules. Dr. Larry Gold, CEO of SomaLogic, Boulder, USA showed how biomarkers can be identified using aptamers. Based on aptamers, SomeLogic introduced a proteomics platform with which it is possible to quantify a multitude of proteins in one approach.
NMI is leading in the implementation of new proteomics results
Simultaneous, miniaturised approaches have received a boom over the last years, both in research as well is in industrial applications. As the NMI itself is a leader in the development of miniaturised immunoassay approaches, Dr. Thomas Joos described the enormous range of applications and new, innovative developments at the NMI. These developments include innovative methods that enable it to measure several dozen analytes in small amounts of sample, for example in 96-well format cell cultures.

Dr. Oliver Poetz, also researching at the NMI in Reutlingen, completed the round of excellent presentations with a talk on “Triple X Proteomics”. Working in the team of Thomas Joos, Poetz is developing peptide-specific capture antibodies (TXP antibodies) that can be used to enrich peptide groups sharing the same terminals sequence. Mass spectrometry readout allows the detection of these peptides. This approach makes it possible to overcome the currently problematic species-specificity of antibodies and generate antibodies that can be used for the detection of proteins in plants, animals and humans.

Source: NMI

« back